Daiwa Securities Group’s ImmunityBio IBRX Stock Holding History

Daiwa Securities Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$464K	Buy	+199,200	New	+$1.36M	﹤0.01%	928

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Daiwa Securities Group's IBRX Position: Q1 2026 in Review

Daiwa Securities Group increased its ImmunityBio (IBRX) stake by 6,178% in Q1 2026, buying an estimated $1.34M and bringing the position to 199,200 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #704.

Daiwa Securities Group first reported a position in IBRX in Q1 2018 and has held it in 25 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Daiwa Securities Group held 199,200 shares of ImmunityBio worth $1.53M as of Q1 2026.
Daiwa Securities Group bought 196,027 ImmunityBio shares in Q1 2026, an estimated $1.34M.
ImmunityBio made up ﹤0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #704 holding.
Daiwa Securities Group first reported a position in ImmunityBio in Q1 2018 and has held it in 25 quarters since.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.